(288 days)
No
The device description and intended use focus on the physical properties and radioactive nature of the brachytherapy source. There is no mention of AI, ML, image processing, or any computational analysis that would suggest the use of such technologies. The performance studies mentioned are related to dosimetry and biocompatibility, not algorithmic performance.
Yes
The device is described as "intended for permanent interstitial implantation for the treatment of selected localized tumors" and works by delivering radioactive palladium for therapeutic effect, directly treating diseases.
No
The device is described as a "Radionuclide Brachytherapy Source" intended for permanent interstitial implantation for the treatment of tumors. It uses radioactive palladium to treat deep-seated tumors, which is a therapeutic function, not a diagnostic one.
No
The device is a physical, permanently implanted radioactive source, not a software-only device.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the treatment of localized tumors through permanent interstitial implantation of a radioactive source. This is a therapeutic intervention, not a diagnostic test performed on samples taken from the body.
- Device Description: The device is a radioactive implant designed to deliver radiation directly to a tumor. This is a physical device used for treatment, not a reagent or instrument used to analyze biological samples.
- Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring specific analytes
- Providing information for diagnosis, monitoring, or prognosis
The device is a therapeutic medical device used in brachytherapy.
N/A
Intended Use / Indications for Use
The ATI Medical, Inc. IsoRod Pd-103 Radionuclide Brachytherapy Source is intended for permanent interstitial implantation for the treatment of selected localized tumors with low to moderate radiosensitivity. They are used either as primary treatment for tumors such as those of the head, neck, lung, intra-abdominal, pancreas, prostate, and unresectable tumors, or for residual disease after excision of primary or secondary tumors. IsoRod Pd-103 implants may be used concurrently with or following treatment with other interventions, such as external beam therapy or chemotherapy.
Product codes
90 KXK
Device Description
The IsoRod implant is a permanently implanted, radioactive device, designed for the treatment of deep- seated tumors. IsoRod implants are comprised of base metallic rods that are coated with radioactive palladium. The radioactive palladium is then encapsulated with a metallic coating.
The base rod is composed of a palladium/cobalt alloy. The rod is 1 millimeter and 10 millimeters in length. The thin layer (0.2 micron) that comprises the radioactive layer is a combination of radioactive and non-radioactive palladium (Pd-103 and Pd-102 respectively). The encapsulation layer of 6-8 microns is pure palladium, a metal that is utilized in permanent implants based on its favorable biocompatibility characteristics.
The activity of each IsoRod implant is between 0.5 mCi and 3.0 mCi. The source is exceptionally isotropic based on the fact that the radioactive material is evenly deposited on the source and is shielded in every direction only by the thin layer of non-radioactive palladium.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
head, neck, lung, intra-abdominal, pancreas, prostate
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The dosimetry of the IsoRod implants was determined by Monte Carlo analysis at UCLA using the MCNP P version 4C Monte Carlo code developed at Los Alamos National Laboratory. Physical dose measurements in a phantom will be completed prior to marketing.
The results of the biocompatibility tests are summarized at Appendix 7 and indicate that the IsoRod Pd-103 implant is biocompatible under the conditions of intended use.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5730 Radionuclide brachytherapy source.
(a)
Identification. A radionuclide brachytherapy source is a device that consists of a radionuclide which may be enclosed in a sealed container made of gold, titanium, stainless steel, or platinum and intended for medical purposes to be placed onto a body surface or into a body cavity or tissue as a source of nuclear radiation for therapy.(b)
Classification. Class II (special controls). A prostate seeding kit intended for use with a radionuclide brachytherapy source only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Ko20683
510(k) SUMMARY
DEC 1 7 2002
Name of 510(k) sponsor: Address:
ATI Medical, Inc. 10954-A Via Frontera San Diego, CA 92129
Telephone: 858 487-7243 Fax: 858 487-7763
Contact information:
Michael Wienholt, RAC Regulatory Affairs Manager ATI Medical, Inc.
Telephone: 858 487-7243, ext. 28 Fax: 858 487-7763 E-mail: mwienholt@atimedical.com
| Date summary prepared: | March 2, 2002 |
|---|---|
| Proprietary name of device: | IsoRod Pd-103 Implant |
| Generic/classification name: | Brachytherapy Source |
| Product code (classification): | Source, Radionuclide, Brachytherapy |
| 21 C.F.R. § 892.5730 |
Legally Marketed Predicate Devices:
GENETRA (K013660) TheraSeed Palladium (K010283) InterSeed (K973328)
Device Description and Technological Characteristics:
The IsoRod implant is a permanently implanted, radioactive device, designed for the treatment of deep- seated tumors. IsoRod implants are comprised of base metallic rods that are coated with radioactive palladium. The radioactive palladium is then encapsulated with a metallic coating.
The base rod is composed of a palladium/cobalt alloy. The rod is 1 millimeter and 10 millimeters in length. The thin layer (0.2 micron) that comprises the radioactive layer is a combination of radioactive and non-radioactive palladium (Pd-103 and Pd-102 respectively). The encapsulation layer of 6-8 microns is pure palladium, a metal that is utilized in permanent implants based on its favorable biocompatibility characteristics.
The activity of each IsoRod implant is between 0.5 mCi and 3.0 mCi. The source is exceptionally isotropic based on the fact that the radioactive material is evenly deposited on the source and is shielded in every direction only by the thin layer of non-radioactive palladium.
1
Intended Use
The ATI Medical, Inc. IsoRod Pd-103 Radionuclide Brachytherapy Source is intended for permanent interstitial implantation for the treatment of selected localized turnors with low to moderate radiosensitivity. They are used either as primary treatment for tumors such as those of the head, neck, lung, intra-abdominal, pancreas, prostate, and unresectable turnors, or for residual disease after excision of primary or secondary tumors. IsoRod Pd-103 implants may be used concurrently with or following treatment with other interventions, such as external beam therapy, hyperthermia, or chemotherapy.
Testing
The dosimetry of the IsoRod implants was determined by Monte Carlo analysis at UCLA using the MCNP P version 4C Monte Carlo code developed at Los Alamos National Laboratory. Physical dose measurements in a phantom will be completed prior to marketing.
The results of the biocompatibility tests are summarized at Appendix 7 and indicate that the IsoRod Pd-103 implant is biocompatible under the conditions of intended use.
Conclusions
The ATI Medical, Inc. IsoRod Pd-103 Implant has the same indications for use and similar technological characteristics (e.g., isotope; apparent activity) as the predicate devices. Biocompatibility testing has established that IsoRod implants are biocompatible under the conditions of intended use.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus symbol. The logo is black and white.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 7 2002
Mr. Michael Wienholt, RAC Director, Regulatory Affairs & QA ATI Medical, Inc. 10954 Via Frontera, Suite A SAN DIEGO CA 92127
Re: K020683 Trade/Device Name: IsoRod Pd-103 Implant Brachytherapy Source .. Regulation Number: 21 CFR 892.5730 Regulation Name: Radionuclide brachytherapy source Regulatory Class: II Product Code: 90 KXK Dated: September 17, 2002 Received: September 18, 2002
Dear Mr. Wienholt:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 . . .
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 8xx.1xxx | (301) 594-4591 |
|---|---|
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |
Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours.
Nancy C. Snydor
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
ATI Medical, Inc. Premarket Notification 510(k) - IsoRod Pd-103 Implants
INDICATIONS FOR USE STATEMENT
| Applicant: | ATI Medical, Inc. |
|---|---|
| 510(k) Number: | K020683 |
| Device Name: | IsoRod Pd-103 Radionuclide Brachytherapy Source (implant) |
Indications for Use:
The ATI Medical, Inc. IsoRod Pd-103 Radionuclide Brachytherapy Source is intended for permanent interstitial implantation for the treatment of selected localized tumors with low to moderate radiosensitivity. They are used either as primary treatment for tumors such as those of the head, neck, lung, intra-abdominal, pancreas, prostate, and unresectable tumors, or for residual disease after excision of primary or secondary tumors. IsoRod Pd-103 implants may be used concurrently with or following treatment with other interventions, such as external beam therapy or chemotherapy.
(PLEASE DO NOT WRITE BELOW THIS LINE)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V
OT
Over-the Counter Use
Daniel h. Lagemann
(Division Sign-Off)
Division of Reproduct and Radiological Devi 510(k) Number